Keyphrases
Antiviral Therapeutics
100%
Antiviral Treatment
20%
CC Genotype
20%
Chronic Hepatitis C
100%
Genotype
80%
Genotype 1
40%
Genotype 2
20%
Genotype Models
20%
Hemoglobin
20%
Hemoglobin Reduction
20%
Hepatitis C
100%
Hepatitis C Virus Genotype 2
60%
Hepatitis C Virus Genotypes
40%
Hepatocellular Carcinoma
20%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
100%
IL28B
80%
Inosine Triphosphatase
80%
Logistic Regression Analysis
20%
Odds Ratio
40%
Partial Splenic Embolization
20%
Pegylated Interferon
20%
Platelets
40%
Premature Discontinuation
20%
Pretreatment Variables
20%
Ribavirin
20%
Ribavirin Treatment
20%
Rs8099917
20%
Splenectomy
20%
Sustained Virological Response
80%
Therapeutic Potential
100%
Thrombocytopenia
100%
Treatment Discontinuation
20%
TT Genotype
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antivirus Agent
100%
Chronic Hepatitis C
100%
Hepatitis C Virus Genotype 1
40%
Hepatitis C Virus Genotype 2
60%
Inosine
80%
Insulin Resistance
100%
Interleukin 28B
80%
Liver Cell Carcinoma
20%
Peginterferon
20%
Polyethylene Glycol
20%
Prematurity
20%
Ribavirin
40%
Thrombocytopenia
100%
Immunology and Microbiology
Hepatitis C
100%
Hepatitis C Virus Genotype 1
40%
Hepatitis C Virus Genotype 2
60%
Homeostasis
100%
Insulin Resistance
100%
Interleukin 28B
80%
Pegylated Interferon
20%
Platelet
40%
Ribavirin
40%
Biochemistry, Genetics and Molecular Biology
Genotyping
100%
Hepatitis C Virus Genotype 1
25%
Hepatitis C Virus Genotype 2
37%
Homeostasis
62%
Inosine Triphosphatase
50%
Insulin Resistance
62%
Interferon
12%
Interleukin 28B
50%
Platelet
25%
Ribavirin
25%
Thrombocytopenia
100%